The Biden-Harris Administration announced that it has reached agreements for new, lower prices for all 10 drugs selected for negotiations. “These negotiated drugs are some of the most expensive and most frequently dispensed drugs in the Medicare program and are used to treat conditions such as heart disease, diabetes, and cancer,” the Department of Health and Human Services said in a statement. The new prices will go into effect for people with Medicare Part D prescription drug coverage beginning January 1, 2026. The negotiated prices range from 38% to 79% discounts off of list prices. About nine million people with Medicare use at least one of the 10 drugs selected for negotiation, according to the HHS. Publicly traded companies in the large pharma space include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson Wins Critical Support from Plaintiffs for $6.5B Settlement
- J&J clears key hurdle for $6.5B lawsuit resolution, Bloomberg reports
- Legend Biotech price target raised to $76 from $70 at Scotiabank
- Johnson & Johnson (JNJ): An Undervalued Dividend King With Strong Financials
- Coca-Cola (KO) Raises €1B with Euro Bond Issuance